BioVie Files S-1 for Up to $50M Best-Efforts Offering to Stave Off Cash Crunch

summarizeSummary

BioVie Inc. filed an S-1 to raise up to $50 million in a best-efforts offering, a critical financing for the cash-strapped biotech as it nears key clinical data readouts.

check_boxKey Events · Financing and Capital Events · BIVI

• Up to $50M Best-Efforts Offering

  BioVie registered up to $50 million of Class A common stock and pre-funded warrants in a best-efforts offering with ThinkEquity as placement agent. No minimum offering amount is required, and the company may sell fewer than all securities offered.

• Cash Runway Pressure

  As of March 31, 2026, BioVie had $13.1 million in cash and used $14.9 million in operations over the prior nine months. The company has a going-concern warning and less than eight months of cash runway, making this offering critical to fund operations.

• Dilution Risk for Existing Holders

  If the full $50 million is raised at the current $1.80 stock price, approximately 27.8 million new shares would be issued, representing roughly 370% dilution to the existing 7.5 million shares outstanding. The actual dilution will depend on the final offering price and amount sold.

• Placement Agent Terms

  ThinkEquity will receive a 7.0% placement agent fee, a 0.5% non-accountable expense allowance, and warrants to purchase 5% of the aggregate shares sold at 125% of the public offering price. The company also granted a three-month right of first refusal for future equity offerings.

auto_awesomeAnalysis · BIVI · Life Sciences

Facing a going-concern warning and less than eight months of cash runway, clinical-stage biotech BioVie is attempting a survival raise of up to $50 million through a best-efforts offering. As of March 31, 2026, the company held $13.1 million in cash after burning $14.9 million in operations over the prior nine months. Without this capital, it risks running out of money before key Phase 2b Parkinson's data expected in late summer 2026. The best-efforts structure carries no guarantee of any funds raised, and the absence of a minimum offering amount adds execution risk. If completed, existing shareholders face significant dilution, especially at the current $1.80 stock price, which sits near the low end of the company's recent trading range.